EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access

Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study

Alexander Kutz iD, Dae Hyun Kim, Jun Liu, Medha N Munshi iD, Elisabetta Patorno iD

Diabetes Care · 2025

DOI: 10.2337/dc24-1795 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes Care, 2025. Verfasst von Alexander Kutz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, Novo Nordisk, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To assess prescribing trends of glucose-lowering medications in the last year of life among older adults with type 2 diabetes (T2D) and explore whether frailty is associated with differential prescribing. RESEARCH DESIGN AND METHODS In this observational cohort study of Medicare beneficiaries aged ≥67 years (2015–2019) with T2D, we assessed temporal trends in prescribing a glucose-lowering medication, stratified by frailty. The main outcome included glucose-lowering medication fills within 1 year of death. RESULTS Among 975,407 community-dwelling Medicare beneficiaries with T2D, the use of glucose-lowering medications within 1 year of death slightly increased from 71.4% during the first 6-month period in 2015 to 72.9% (standardized mean difference [SMD] −0.03) during the second 6-month period in 2019. The most pronounced increase in use was observed for metformin (40.7% to 46.5%, SMD −0.12), whereas the largest decrease was observed for sulfonylureas (37.0% to 31.8%, SMD 0.11). Overall glucose-lowering medication use decreased from 66.1% in the 9 to 12 months before death to 60.8% in the last 4 months of life (SMD 0.11; P < 0.01), driven by reduced noninsulin medication use. The use of short-acting and long-acting insulin both increased near death, with frailer individuals more likely to receive insulin. Sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, although less common, became more frequent in more recent years. CONCLUSIONS The use of glucose-lowering medications declined in the last year of life, mainly due to reduced noninsulin use. Insulin use increased near death, particularly among frailer individuals, highlighting the need for careful end-of-life management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansAgedMaleFemaleCohort StudiesAged, 80 and overSulfonylurea CompoundsMetforminUnited StatesTerminal CareMedicare

Substanzen

Hypoglycemic AgentsSulfonylurea CompoundsMetformin

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA.
  • Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
  • Joslin Diabetes Center, Harvard Medical School, Boston, MA.
  • Beth Israel Deaconess Medical Center, Boston, MA.

ORCID-Profile: Alexander Kutz, Medha N Munshi, Elisabetta Patorno

Förderung

  • the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
  • Novo Nordisk
  • NIA NIH HHS
  • NIDDK NIH HHS
  • FDA HHS
  • Patient Centered Outcomes Research Institute
  • Swiss National Science Foundation
  • the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Zitieren

APA

Kutz, A., Kim, D. H., Liu, J., Munshi, M. N., & Patorno, E. (2025). Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study. Diabetes Care. https://doi.org/10.2337/dc24-1795

Vancouver

Kutz A, Kim DH, Liu J, Munshi MN, Patorno E. Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study. Diabetes Care. 2025. doi:10.2337/dc24-1795

BibTeX
@article{Kutz2025,
  author = {Kutz, Alexander and Kim, Dae Hyun and Liu, Jun and Munshi, Medha N and Patorno, Elisabetta},
  title = {Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc24-1795}
}
Kostenlos starten →